Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Five Pennsylvania counties are investigating possible fraudulent voter applications and mail-in ballot applications in the ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Against several returning drivers with a point to prove, reigning British F4 champion Louis Sharp achieved an unprecedented ...

The USF Pro Championships Presented by Continental Tire has announced it will increase horsepower on road and street courses ...

Prosecutors allege that Dieter S. fought for pro-Russian separatists in eastern Ukraine between 2014 and 2016, participating ...

The Deseret News is providing live coverage of Saturday’s game between Utah and BYU. Check back for updates throughout the ...

The following is a summary of “Evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective ...

HSBC, CGSI and UOBKH have kept their target price unchanged at $3.65, $3.70 and $3.58, respectively. Citi has kept its target price of $3.60, while RHB has a target price of $3.60 as well.

New Darzelex SC quadruplet regimen approved by European Commission for newly diagnosed multiple myeloma patients.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...